iPhone Warning: This new technology could make the iPhone obsolete
Warning: One day, that shiny new iPhone in your hand will be worthless. And that day isn’t as far away as you think.

Because all the 6.3 billion smartphones on the planet will be replaced by the revolutionary new device in this little black box.
Apple’s CEO has called this “the next big thing”

AEZ Insider Trading (43844 (AEZ.TO))

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): C$53,638.20
Insider Selling (Last 12 Months): C$0.00

43844 (AEZ.TO) Insider Trading History Chart

This chart shows the insider buying and selling history at 43844 (AEZ.TO) by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

43844 (AEZ.TO) Share Price & Price History

Current Price: C$0.00
Price Change: +0.30 (1.20%)
As of 12/31/1969 06:45 PM ET

This chart shows the closing price history over time for AEZ up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Man who called 2020 Crash warns of huge event in 2022
A historic event in 2022 will cause a massive shift in the wealth divide. It could leave thousands of Americans under age 50 better off… while retirees will be left holding the scraps.
Details here…

43844 (AEZ.TO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/24/2021Klaus PauliniDirectorBuy15,000C$0.83C$12,474.0055,000
4/12/2021Carolyn EgbertDirectorBuy30,000C$1.37C$41,164.2031,920
See Full Table
Insider Trading at 43844 (AEZ.TO)?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for 43844 (AEZ.TO) and related companies.

SEC Filings (Institutional Ownership Changes) for 43844 (AEZ.TO) (TSE:AEZ)

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The Company's principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Company focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company's direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.
Read More on 43844 (AEZ.TO)

Today's Range

Now: N/A

50 Day Range


52 Week Range

Now: N/A


1,000 shs

Average Volume

12,504 shs

Market Capitalization


P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of 43844 (AEZ.TO)?

43844 (AEZ.TO)'s top insider investors include:
  1. Klaus Paulini (Director)
  2. Carolyn Egbert (Director)
“Move your money by early 2022,” Wall Street legend warns
A new form of technology will cause a massive shift in the wealth divide in 2022. Do you own the stocks that will be affected?
Details here…